The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / New Paradigm Investing


Subject:  Re: Binary Event Alert Date:  12/9/2009  1:28 AM
Author:  mtnanhu Number:  44191 of 118191

Yes, positive result of study 901 will be a huge boost to NBIX and if ran under the old matrix, elagolix should be way into phase III by now.

However, this management has NO respect from me.
1. Look at their track record with Indiplon
2. Look at how they handle study 702 - yes, it is a brand new recording system. But it seems to me that they have NO understanding about the "symptoms" of non-menstrual pain whatsoever and have no clue what it takes to run a successful trial. Any experienced team would NOT have made such mistake.

I would go deep on elagolix if it is in good hands such as BMRN; with NBIX, a touch down is a much more nervous bet.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us